Ceravolo

Abstract

Gemcitabine is considered the gold standard treatment for unresectable pancre-atic adenocarcinoma. Intra-arterial drug administration had shown some interesting results in small phase II studies.

In this study, patients were randomly assigned to receive gemcitabine at a dose of 1,000 mg/m² over 30 minutes intravenously weekly for 7 weeks, followed by 1 week of rest, then weekly for 3 weeks every 4 weeks or FLEC: 5-fluoruracil 1,000 mg/m², leucovorin 100 mg/m², epirubicin 60 mg/m², carboplatin 300 mg/m² infused bolus intra-arterially into celiac axis at a 3-week interval 3 times or 5-fluor-ouracil 400 mg/m2 plus folinic acid 20 mg/m2 for 5 days every 4 weeks for 6 cycles. The primary endpoint was overall survival, while time to treatment failure, response rate, clinical benefit response were secondary endpoints. Sixty-seven patients were randomly allocated gemcitabine and 71 were allocated FLEC intra-arterially. Patients treated with FLEC lived for significantly longer than patients on gemcitabine (p=0.036). Survival at 1 year increased from 21% in the gemcitabine group to 35% in the FLEC group. Median survival was 7.9 months in the FLEC group and 5.8 months in the gemcitabine group. Median time to treatment failure was longer with FLEC (5.3 vs 4.2 months for FLEC vs gemcitabine respectively; p=0.013). Clinical benefit was similar in both groups (17.9% for gemcitabine and 26.7% for FLEC; p=NS). CT-scan partial response was similar in both groups (5.9% for gemcitabine and 14% for FLEC; p=NS). Toxicity profiles were different.

Compared with gemcitabine, the FLEC regimen given intra-arterially improved survival in patients with unresectable pancreatic adenocarcinoma.

Keywords:

• Gemcitabine
• FLEC regimen
• 5-fluorouracil
• folinic acid
• pancreatic cancer
• intra-arterial chemotherapy